Analyst: Pharma a safe haven; Neoprobe shareholders approve sale of radiation detector biz;

@FiercePharma: J&J chief gets chance to advise Obama on job creation. How about this: Avoid recalls, Mr. President. Article | Follow @FiercePharma

> A Jefferies & Co. analyst says pharma stocks will become a defensive sector for investors despite such challenges as patent expirations. Story

> Neoprobe shareholders have approved the company's deal to sell its chief source of revenue as the company bets on drug development. Report

> A new sub-analysis of a set of patients from the TRITON-TIMI 38 study showed that treatment with prasugrel in combination with aspirin was associated with a 26% relative risk reduction in the combined primary endpoint of cardiovascular death, myocardial infarction or stroke, compared with treatment with clopidogrel. Eli Lilly release

> Foster City officials are excited by the prospects of Gilead Sciences expanding its facilities, and say they have a plan to keep down traffic. News 

> West Pharmaceutical Services will expand its R&D center in St. Petersburg, FL. West's advanced development center will focus on new elastomer formulations, process technologies and products for its global component manufacturing network. West release

Biotech News

@FierceBiotech: MA-based Proteon Therapeutics has raised $15.2M in an equity and options financing. Item | Follow @FierceBiotech

@JohnCFierce: Generic drug makers agree to program in which they pay an initial $299M to speed up FDA reviews, clear a backlog. Story | Follow @JohnCFierce

Sign up for our FREE newsletter for more news like this sent to your inbox!

@RyanMFierce: Broad Institute CIO says genome research outfit on way to filling 10-petabyte capacity. Interview | Follow @RyanMFierce

@MaureenFierce: Study: Illegal online pharmacies are manipulating Internet searches to send consumers to their sites. Report | Follow @MaureenFierce

> Analysts see an upside after market swings bludgeon biotechs. Story

> Acorda CEO Cohen throws his weight behind new biotech trailblazer. Report

> Embera adds $4.5 million in Series A cash. News

> Pulmatrix reels in $14M for its work on COPD, cystic fibrosis. Story

Biotech IT News

> Accelyrs' revenue Q2 up 86% after mergers. Report

> New CIO reach tackles IT needs at the Broad Institute. More

> Virtual rats in the works to aid disease research. Details

> Perceptive Informatics does part in Parexel's losing Q4. Story

> BMS taps GNS Healthcare for computer model of information. News

> Medidata sees CFO resign after Q2 growth. Article

Medical Device News

> Device industy sees more investment, fewer deals. Details

> Sen. Brown visits Covidien, lobbies against device tax. News

> Southern Diagnostic Laboratories bought by Solstas. Story

> NEJM authors come out in support of IOM report. Article

And Finally... MIT researchers say they've designed a drug that could potentially cure the common cold, flu and even Ebola. Item

Suggested Articles

After Purdue’s record opioid settlement, more deals could be on the way. But that doesn’t mean all defendants are prepared to go quietly.

Now in their third quarter on the market, Gilead's own Epclusa and Harvoni generics have together grabbed more than 20% of the U.S. hep C market.

Purdue is seeking bankruptcy after inking a $10 billion-plus opioid settlement with thousands of cities and counties, plus two dozen states.